MyFinsight
Home
Blog
About
Proceeds from note
purchase agreement
$35,000K
Proceeds from issuance of
series b preferred...
$25,000K
Proceeds from stock
purchase and conversion...
$5,000K
Proceeds from issuance of
common stock in...
$2,250K
(450.12%↑ Y/Y)
Proceeds from warrant
exercises
$1,663K
Exercise of stock options
$1,222K
(24340.00%↑ Y/Y)
Net cash provided by
financing activities
$68,498K
(220.52%↑ Y/Y)
Canceled cashflow
$1,637K
Net increase in
cash, cash...
$43,821K
Canceled cashflow
$24,677K
Issuance costs
attributed to note purchase...
$1,113K
Payments of stock
issuance costs
$491K
Share repurchases for
the payment of...
$33K
(-8.33%↓ Y/Y)
Fair value change in
instruments measured at fair...
-$43,909K
(-1279.72%↓ Y/Y)
Stock-based compensation
$2,871K
(58.71%↑ Y/Y)
Accrued expenses
$1,236K
(173.75%↑ Y/Y)
Issuance costs related to
financing activities
$1,113K
(-16.75%↓ Y/Y)
Accounts receivable
-$954K
(-481.71%↓ Y/Y)
Contract assets and
unbilled receivables
-$755K
(26.77%↑ Y/Y)
Non-cash interest,
related party
$143K
Depreciation
$27K
(0.00%↑ Y/Y)
Net cash used in
operating activities
-$24,677K
(-28.11%↓ Y/Y)
Canceled cashflow
$51,008K
Net and
comprehensive loss
-$73,633K
(-371.58%↓ Y/Y)
Accounts payable
-$1,412K
(17.09%↑ Y/Y)
Prepaids and other
current assets
$640K
(-30.28%↓ Y/Y)
Back
Back
Cash Flow
Opus Genetics, Inc. (IRD)
Opus Genetics, Inc. (IRD)
source: myfinsight.com